Monoclonal antibodies targeting LecLex-related glycans with potent antitumor activity

Clinical Cancer Research

Volumn 21, Issue 13, 2015, Pages 2963-2974

  Chua, Jia Xin ^a   Vankemmelbeke, Mireille ^a   McIntosh, Richard S ^a   Clarke, Philip A ^a   Moss, Robert ^a   Parsons, Tina ^a   Spendlove, Ian ^a   Zaitoun, Abid M ^a   Madhusudan, Srinivasan ^a   Durrant, Lindy G ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE; GLYCAN; LEWIS GLYCAN; MONOCLONAL ANTIBODY FG88.2; MONOCLONAL ANTIBODY FG88.7; SAPONIN; UNCLASSIFIED DRUG; BLOOD GROUP LEWIS SYSTEM; MONOCLONAL ANTIBODY; POLYSACCHARIDE; TUMOR MARKER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CELL KILLING; CELL MEDIATED CYTOTOXICITY; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; FEMALE; HUMAN; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; LONG TERM SURVIVAL; LYSOSOME; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; STOMACH CANCER; TISSUE DISTRIBUTION; TISSUE SPECIFICITY; ANIMAL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BAGG ALBINO MOUSE; BLOOD GROUP LEWIS SYSTEM; DRUG SCREENING; IMMUNOLOGY; LIVER NEOPLASMS, EXPERIMENTAL; METABOLISM; NUDE MOUSE; SECONDARY; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CELL LINE, TUMOR; HUMANS; LEWIS BLOOD-GROUP SYSTEM; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE, INBRED BALB C; MICE, NUDE; POLYSACCHARIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84941952024     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-3030     Document Type: Article

References (43)

1. Christiansen MN, Chik J, Lee L, Anugraham M, Abrahams JL, Packer NH. Cell surface protein glycosylation in cancer. Proteomics 2014;14:525-46.
2. Dalziel M, Crispin M, Scanlan CN, Zitzmann N, Dwek RA. Emerging principles for the therapeutic exploitation of glycosylation. Science 2014; 343:1235681.
3. Daniotti JL, Vilcaes AA, Torres Demichelis V, Ruggiero FM, Rodriguez- Walker M. Glycosylation of glycolipids in cancer: basis for development of novel therapeutic approaches. Front Oncol 2013;3:306.
4. Hakomori S. Glycosylation defining cancer malignancy: newwine in an old bottle. Proc Natl Acad Sci U S A 2002;99:10231-3.
5. Fuster MM, Esko JD. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer 2005;5:526-42.
6. Hakomori SI, Cummings RD. Glycosylation effects on cancer development. Glycoconj J 2012;29:565-6.
7. Stanley P, Cummings RD. Structures common to different glycans. In:Varki A, Cummings RD, Esko JD, et al., editors. Essentials of glycobiology. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, New York; 2009.
8. Hakomori S, Andrews HD. Sphingoglycolipids with Leb activity, and the co-presence of Lea-, Leb-glycolipids in human tumor tissue. Biochim Biophys Acta 1970;202:225-8.
9. Inagaki H, Sakamoto J, Nakazato H, Bishop AE, Yura J. Expression of Lewis (a), Lewis(b), and sialated Lewis(a) antigens in early and advanced human gastric cancers. J Surg Oncol 1990;44:208-13.
10. Sakamoto J, Furukawa K, Cordon-Cardo C, Yin BW, Rettig WJ, Oettgen HF, et al. Expression of Lewisa, Lewisb, X, and Y blood group antigens in human colonic tumors and normal tissue and in human tumor-derived cell lines. Cancer Res 1986;46:1553-61.
11. Blaszczyk M, Pak KY, Herlyn M, Sears HF, Steplewski Z. Characterization of Lewis antigens in normal colon and gastrointestinal adenocarcinomas. Proc Natl Acad Sci U S A 1985;82:3552-6.
12. Cazet A, Julien S, Bobowski M, Burchell J, Delannoy P. Tumourassociated carbohydrate antigens in breast cancer. Breast Cancer Res 2010;12:204.
13. Durrant LG, Noble P, Spendlove I. Immunology in the clinic review series; focus on cancer: glycolipids as targets for tumour immunotherapy. Clin Exp Immunol 2012;167:206-15.
14. Rabu C, McIntosh R, Jurasova Z, Durrant L. Glycans as targets for therapeutic antitumor antibodies. Future Oncol 2012;8:943-60.
15. Yang MC, Hsu FL, Handa K, Hakomori S, Lee MH, Liu LY, et al. Human monoclonal antibody GNX-8 directed to extended type 1 chain: specific binding to human colorectal cancer. Int J Cancer. 2009 Dec 21; doi:10.1002/ijc.25131.
16. Capurro M, Ballare C, Bover L, Portela P, Mordoh J. Differential lytic and agglutinating activity of the anti-Lewis(x) monoclonal antibody FC- 2.15 on human polymorphonuclear neutrophils and MCF-7 breast tumor cells. In vitro and ex vivo studies. Cancer Immunol Immunother 1999;48:100-8.
17. Ballare C, Portela P, Schiaffi J, Yomha R, Mordoh J. Reactivity of monoclonal antibody FC-2.15 against drug resistant breast cancer cells. Additive cytotoxicity of adriamycin and taxol with FC-2.15. Breast Cancer Res Treat 1998;47:163-70.
18. Watanabe M, Ohishi T, Kuzuoka M, Nudelman ED, Stroud MR, Kubota T, et al. In vitro and in vivo antitumor effects of murine monoclonal antibody NCC-ST-421 reactingwith dimeric Le(a) (Le(a)/Le(a)) epitope. Cancer Res 1991;51:2199-204.
19. Stroud MR, Levery SB, Martensson S, Salyan ME, Clausen H, Hakomori S. Human tumor-associated Le(a)-Le(x) hybrid carbohydrate antigen IV3 (Gal beta 1->3[Fuc alpha 1->4]GlcNAc)III3FucnLc4 defined by monoclonal antibody 43-9F: enzymatic synthesis, structural characterization, and comparative reactivity with various antibodies. Biochemistry 1994;33: 10672-80.
20. Durrant LG, Harding SJ, Green NH, Buckberry LD, Parsons T. A new anticancer glycolipid monoclonal antibody, SC104, which directly induces tumor cell apoptosis. Cancer Res 2006;66:5901-9.
21. Sawada R, Sun SM, Wu X, Hong F, Ragupathi G, Livingston PO, et al. Human monoclonal antibodies to sialyl-Lewis (CA19.9) with potent CDC, ADCC, and antitumor activity. Clin Cancer Res 2011; 17:1024-32.
22. Watson SA, Morris TM, Crosbee DM, Hardcastle JD. A hepatic invasive human colorectal xenograft model. Eur J Cancer 1993;29A:1740-5.
23. Noble P, Spendlove I, Harding S, Parsons T, Durrant LG. Therapeutic targeting of Lewis(y) and Lewis(b)with a novel monoclonal antibody 692/ 29. PLoS One 2013;8:e54892.
24. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 2004;10:7252-9.
25. Watson NF, Madjd Z, Scrimegour D, Spendlove I, Ellis IO, Scholefield JH, et al. Evidence that the p53 negative/Bcl-2 positive phenotype is an independent indicator of good prognosis in colorectal cancer: a tissue microarray study of 460 patients. World J Surg Oncol 2005; 3:47.
26. Duncan TJ, Rolland P, Deen S, Scott IV, Liu DT, Spendlove I, et al. Loss of IFN gamma receptor is an independent prognostic factor in ovarian cancer. Clin Cancer Res 2007;13:4139-45.
27. Abdel-Fatah T, Arora A, Gorguc I, Abbotts R, Beebeejaun S, Storr S, et al. Are DNA repair factors promising biomarkers for personalized therapy in gastric cancer? Antioxid Redox Signal 2013;18:2392-8.
28. Storr SJ, Zaitoun AM, Arora A, Durrant LG, Lobo DN, Madhusudan S, et al. Calpain system protein expression in carcinomas of the pancreas, bile duct and ampulla. BMC Cancer 2012;12:511.
29. Kohls MD, Lappi DA. Mab-ZAP: a tool for evaluating antibody efficacy for use in an immunotoxin. BioTechniques 2000;28:162-5.
30. Price MR, Pimm MV, Page CM, Armitage NC, Hardcastle JD, Baldwin RW. Immunolocalization of the murine monoclonal antibody, 791T/36 within primary human colorectal carcinomas and identification of the target antigen. Br J Cancer 1984;49:809-12.
31. Nakagoe T, Fukushima K, Nanashima A, Sawai T, Tsuji T, Jibiki M, et al. Expression of Lewis(a), sialyl Lewis(a), Lewis(x) and sialyl Lewis(x) antigens as prognostic factors in patients with colorectal cancer. Can J Gastroenterol 2000;14:753-60.
32. Kannagi R. Carbohydrate antigen sialyl Lewis a-its pathophysiological significance and inductionmechanism in cancer progression. Chang Gung Med J 2007;30:189-209.
33. Weston BW, Hiller KM, Mayben JP, Manousos GA, Bendt KM, Liu R, et al. Expression of human alpha(1,3)fucosyltransferase antisense sequences inhibits selectin-mediated adhesion and liver metastasis of colon carcinoma cells. Cancer Res 1999;59:2127-35.
34. Inagaki Y, Gao J, Song P, Kokudo N, Nakata M, Tang W. Clinicopathological utility of sialoglycoconjugates in diagnosing and treating colorectal cancer. World J Gastroenterol 2014;20:6123-32.
35. Loo D, Pryer N, Young P, Liang T, Coberly S, King KL, et al. The glycotopespecific RAV12 monoclonal antibody induces oncosis in vitro and has antitumor activity against gastrointestinal adenocarcinoma tumor xenografts in vivo. Mol Cancer Ther 2007;6:856-65.
36. Tan HL, Fong WJ, Lee EH, Yap M, Choo A. mAb 84, a cytotoxic antibody that kills undifferentiated human embryonic stem cells via oncosis. Stem Cells 2009;27:1792-801.
37. Zhang C, Xu Y, Gu J, Schlossman SF. A cell surface receptor defined by a mAbmediates a unique type of cell death similar to oncosis. Proc Natl Acad Sci U S A 1998;95:6290-5.
38. Hernandez AM, Rodriguez N, Gonzalez JE, Reyes E, Rondon T, Grinan T, et al. Anti-NeuGcGM3 antibodies, actively elicited by idiotypic vaccination in nonsmall cell lung cancer patients, induce tumor cell death by an oncosis-like mechanism. J Immunol 2011; 186:3735-44.
39. Alduaij W, Ivanov A, Honeychurch J, Cheadle EJ, Potluri S, Lim SH, et al. Novel type II anti-CD20 monoclonal antibody (GA101) evokeshomotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood 2011;117:4519-29.
40. Krysko O, Love Aaes T, Bachert C, Vandenabeele P, Krysko DV. Many faces of DAMPs in cancer therapy. Cell Death Dis 2013;4:e631.
41. Schreiber GJ, Hellstrom KE, Hellstrom I. An unmodified anticarcinoma antibody, BR96, localizes to and inhibits the outgrowth of human tumors in nude mice. Cancer Res 1992;52:3262-6.
42. Consortium for Functional Glycomics FGG. FG88.2 on core H, version 5.1 glycan array. [Internet]. Functional Glycomics Gateway; c2010. Available from: http://www.functionalglycomics.org/glycomics/HServlet?operation=view&sideMenu=no&psId=primscreen-5844. Accessed April 8, 2015.
43. Consortium for Functional Glycomics FGG. FG88.7 on core H, version 5.1 glycan array. [Internet]. Functional Glycomics Gateway; c2010. Available from: http://www.functionalglycomics.org/glycomics/HServlet? operation=view&sideMenu=no&psId=primscreen-5847. Accessed April 8, 2015.